ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 227 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $86,000 | -18.1% | 15,578 | 0.0% | 0.00% | – |
| Q2 2023 | $105,000 | -46.4% | 15,578 | -29.8% | 0.00% | – |
| Q1 2023 | $196,000 | -8.0% | 22,178 | -19.9% | 0.00% | – |
| Q4 2022 | $213,000 | +8.1% | 27,703 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $197,000 | -12.8% | 27,703 | -0.4% | 0.00% | 0.0% |
| Q2 2022 | $226,000 | +41.2% | 27,816 | +144.1% | 0.00% | – |
| Q1 2022 | $160,000 | -61.7% | 11,397 | -7.4% | 0.00% | -100.0% |
| Q3 2021 | $418,000 | -27.9% | 12,311 | -13.3% | 0.00% | -50.0% |
| Q2 2021 | $580,000 | -8.1% | 14,200 | -9.4% | 0.00% | 0.0% |
| Q1 2021 | $631,000 | -62.8% | 15,670 | -45.4% | 0.00% | -71.4% |
| Q4 2020 | $1,698,000 | +68.6% | 28,712 | +38.7% | 0.01% | +40.0% |
| Q3 2020 | $1,007,000 | +60.6% | 20,700 | +59.8% | 0.01% | +66.7% |
| Q2 2020 | $627,000 | -17.1% | 12,950 | -52.4% | 0.00% | -40.0% |
| Q1 2020 | $756,000 | -55.9% | 27,200 | -52.6% | 0.01% | -50.0% |
| Q4 2019 | $1,716,000 | – | 57,375 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |